Telix Pharmaceuticals is trading 4.22% up at A$16.06, though available coverage does not explicitly link the move to the Pixclara announcement.
- On October 6, the company said the first U.S. patients received Pixclara, starting commercial availability of its FDA-approved brain cancer imaging drug.
- The announcement marks a company milestone.
- Broader U.S. equities advanced, while biotech-sector context was negative.